IsoPlexis acquires sequencing methodology IP

By The Science Advisory Board staff writers

May 25, 2021 -- IsoPlexis has acquired an intellectual property (IP) portfolio of 86 patents related to DNA and RNA sequencing, which it is integrating into its single-cell proteomics platforms to enable a series of next-generation assays that incorporate multiple omic modalities.

The company's patent portfolio now includes sequencing methodologies that will increase the depth of resolution into connections between the genome and the proteome of cancer immunology, cell and gene therapy, and neurological disease. The acquired assets will enable integration of IsoPlexis' proprietary proteomics technologies with proprietary sequencing-based technologies.

The company's proprietary functional proteomics platform includes instruments, chip consumables, and software that has the potential to reveal a more complete view of protein function at an individual cellular level, according to the firm.

IsoPlexis launches new personalized lab systems
IsoPlexis has launched two new personalized lab systems, IsoSpark and IsoSpark Duo for high-throughput proteomics.
IsoPlexis launches new COVID-19 proteomics grant challenge
IsoPlexis has unveiled its Single-Cell Proteomics COVID-19 Grant Challenge, which will award 12 of the company's IsoCode or CodePlex chips to two winners...
IsoPlexis, Lonza partner on cell therapy manufacturing
IsoPlexis and Lonza have partnered to advance automated cell therapy manufacturing.
IsoPlexis partners with Columbia for vaccine development
IsoPlexis is partnering with Columbia University's Division of Infectious Diseases to create a vaccine for COVID-19. IsoPlexis' Single-Cell Secretome...

Copyright © 2021 scienceboard.net


Conferences
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter